BioPharmSignal logoBioPharmSignal

Biotech News

SCYNEXIS Announces $40.0 Million Private Placement

SCYNEXIS (SCYX)SCYNEXISFinancing

SCYX (SCYX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is scyx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

SCYXSCYNEXIS2026-03-31 10:40 EST

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ANTXAN2 Therapeutics2026-03-09 11:00 EST

AN2 Therapeutics Announces $40 Million Private Placement Financing

OGENOragenics2025-07-01 12:31 EST

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

ASMBAssembly Biosciences2026-05-22 11:05 EST

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants

VIRIVirios Therapeutics2026-01-12 13:30 EST

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

ASMBAssembly Biosciences2025-08-08 12:05 EST

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

OGENOragenics2025-07-02 20:15 EST

Oragenics Completes Approximately $16.5 Million Offering

SCYXSCYNEXIS2026-06-30 12:00 EST

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SPROSpero Therapeutics2023-11-01 08:05 EST

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

View all latest news

SCYNEXIS

SCYNEXIS is a specialty pharma company focused on anti-infective and antifungal medicines. Its business has been shaped by the commercialization of a narrow product set and pipeline maintenance.

Recent company news

SCYXSCYNEXIS2026-06-30 12:00 EST

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYXSCYNEXIS2026-05-22 20:15 EST

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYXSCYNEXIS2026-05-11 20:23 EST

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYXSCYNEXIS2026-05-07 01:15 EST

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYXSCYNEXIS2026-03-31 10:45 EST

SCYNEXIS Announces $40.0 Million Private Placement

Stock data

Close
3.57 USD
Market cap
50.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States